EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Propensity‐score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II–III anal adenocarcinoma

Sameh Hany Emile iD, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Peige Zhou, Steven D Wexner

Journal of Surgical Oncology · 2023

DOI: 10.1002/jso.27313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2023. Verfasst von Sameh Hany Emile und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida, USA. Hauptthemen laut MEDLINE: Anus Neoplasms, Adenocarcinoma. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anal adenocarcinomas are a rare condition which account for less than 10% of anal cancers. The present study aimed to assess the impact of neoadjuvant therapy on the clinical and pathologic outcomes and overall survival (OS) of patients with stage II–III anal adenocarcinomas after abdominoperineal resection (APR).

Methods

A retrospective cohort study of patients with anal adenocarcinoma in the US National Cancer Database (NCDB) (2010–2020) was conducted. Propensity‐score matching was used to compare patients who received neoadjuvant therapy (neoadjuvant therapy group) to the no‐neoadjuvant group. The primary outcome was 5‐year OS whereas secondary outcomes included conversion to open surgery, hospital stay, surgical margins, 30‐day mortality, 90‐day mortality, and 30‐day readmission.

Results

A total of 742 patients (56% male) with a mean age of 63.6 ± 12.4 years were included. A total of 214 patients in the neoadjuvant group were matched with 107 in the no‐neoadjuvant group. The mean OS was similar between the two groups (47.5 vs. 44.8 months, p = 0.253). Patients who received neoadjuvant therapy had a longer median time between diagnosis and surgery (151 vs. 54 days, p < 0.001), lower 90‐day mortality (1.9% vs. 6.7%, p = 0.046), more pT0 tumors (15.7% vs. 0%), less pT3‐4 tumors (28.4% vs. 36.4%, p = 0.001), less pN1‐2 tumors (22.9% vs. 34.7%, p < 0.001), and less lymphovascular invasion (16.2% vs. 40%, p < 0.001) than the no‐neoadjuvant group. Both groups had similar conversion rates, hospital stay, 30‐day mortality, 30‐day readmission, and positive surgical margins.

Conclusions

Neoadjuvant therapy before APR was associated with significant downstaging of anal adenocarcinomas and lower 90‐day mortality, yet similar OS to patients who were surgically treated without neoadjuvant treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anus NeoplasmsAdenocarcinomaHumansMaleMiddle AgedAgedFemaleNeoadjuvant TherapyRetrospective StudiesNeoplasm StagingTreatment Outcome

Stichwörter der Autor:innen

National Cancer Database Analysisanal adenocarcinomaneoadjuvant therapypathologic outcomespropensity-scoresurvival

Autor:innen und Institutionen

  • Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida, USA.
  • Unit of Colorectal Surgery, Department of General Surgery, Mansoura University Hospitals, Mansoura, Egypt.
  • Department of Surgery and Transplantation, Sheba Medical Center, Ramat-Gan, Israel.
  • Department of General Surgery, Faculty of Medicine, Hadassah Medical Organization, Hebrew University of Jerusalem, Jerusalem, Israel.

ORCID-Profile: Sameh Hany Emile

Zitieren

APA

Emile, S. H., Horesh, N., Garoufalia, Z., Gefen, R., Zhou, P., & Wexner, S. D. (2023). Propensity‐score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II–III anal adenocarcinoma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27313

Vancouver

Emile SH, Horesh N, Garoufalia Z, Gefen R, Zhou P, Wexner SD. Propensity‐score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II–III anal adenocarcinoma. Journal of Surgical Oncology. 2023. doi:10.1002/jso.27313

BibTeX
@article{Emile2023,
  author = {Emile, Sameh Hany and Horesh, Nir and Garoufalia, Zoe and Gefen, Rachel and Zhou, Peige and Wexner, Steven D},
  title = {Propensity‐score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II–III anal adenocarcinoma},
  journal = {Journal of Surgical Oncology},
  year = {2023},
  doi = {10.1002/jso.27313}
}
Kostenlos starten →